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In this study we have identified a functional role for miR-29a in cancer cell invasion and
proliferation. MiRNA expression profiling of human NSCLC cell lines indicated that miR-
29a levels were reduced in more invasive cell lines. Exogenous overexpression of miR-29a
in both lung and pancreatic cancer cell lines resulted in a significant reduction in the inva-
sion phenotype, as well as in proliferation. 2D DIGE proteomic profiling of cells transfected
with pre-miR-29a or anti-miR-29a resulted in the identification of over 100 differentially reg-
ulated proteins. The fold change of protein expression was generally modest – in the range
1.2–1.7-fold. Only 14 were predicted computationally to have miR-29a seed sequences in
their 3 0 UTR region.
Subsequent studies using siRNA to knock down several candidate proteins from the 2D
DIGE experiment identified RAN (a member of the RAS oncogene family) which signifi-
cantly reduced the invasive capability of a model lung cancer cell line.
We conclude that miR-29a has a significant anti-invasive and anti-proliferative effect on
lung cancer cells in vitro and functions as an anti-oncomir. This function is likely mediated
through the post-transcriptional fine tuning of the cellular levels of several proteins, both
directly and indirectly, and in particular we provide some evidence that RAN represents one
of these.
 2009 Elsevier Ltd. All rights reserved.1. Introduction associated with some aspect of cancer, and then tried to iden-MicroRNAs have emerged in recent years as key regulators in
a broad spectrum of cellular functions – and dysfunctions – as
evidenced by the proliferation of reports in the literature
relating to their study. A large proportion of these have been
in the field of cancer research with several focused on the
invasive/metastatic process specifically.1
One of the challenges of studying miRNA function in the
cellular environment is identifying potential protein targets.
Many early studies started with the target gene, often weller Ltd. All rights reserved
fax: +35 317005484.
rron).tify miRNAs that might bind the transcript based on in silico
predictions.2,3 Conversely, in silico analysis has been used to
predict the potential target genes based on the sequence of
a particular miRNA.4 The rules being used to develop these
algorithms are becoming more refined as experimental data
builds, leading to improved predictive capacity of these soft-
ware tools. More recently, high throughput proteomic and
transcriptomic technologies have greatly increased the iden-
tification and understanding of bona fide miRNA targets in
cell lines, tissue samples and in vivo.5.
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stream targets of miR-29a using such approaches. MiR-29a is
found on chromosome 7q32.3 in tandem with miR-29b-1 and
has been reported in studies focused on cancer biomarker
identification6 as well as cancer-related phenotypes in vitro
and in vivo. It has been shown to regulate the levels of Mcl-1
and subsequently increase TRAIL-mediated apoptosis in
malignant cholangiocarcinoma cells.3 TCL-1, the oncogene
implicated in progression of CLL, has been shown to be regu-
lated, at least in part, by the action ofmiR-29a.7 In lung cancer
cell lines miR-29awas shown to reverse aberrant methylation
by down-regulating the expression of DNMT3A and 3B.4
Importantly, a study by Chang and colleagues demonstrated
that miR-29a is a target for suppression by c-myc.8 Preliminary
work in our laboratory identified miR-29a as being differen-
tially expressed in an in vitro model of invasive lung cancer.
In combination these findings point to an important role for
this molecule in maintaining normal cellular function and
behaviour and prompted us to further investigate other po-
tential target proteins and pathways influenced by miR-29a
in our model system.
2. Materials and methods
2.1. Cell culture
Lung carcinoma cell lines, DLKP and DLKP-A9 were main-
tained in ATCC media supplemented with 5% FCS and incu-
bated at 37 C. DLKP is a poorly differentiated, squamous
cell lung carcinoma with a non-invasive phenotype. DLKP-A
is a highly invasive variant generated by chronic exposure
of the parent cell line to the chemotherapeutic drug, Adria-
mycin. PANC-1 cell line is a highly invasive cell line derived
from a pancreatic ductal carcinoma (ATCC) and maintained
in DMEM supplemented with 5% (v/v) FCS and incubated at
37 C.
2.2. Transfection of cells
The cells were transfected in suspension after trypsinisation
with 50 nM siRNA, anti-miR or pre-miR (Applied Biosystems).
For the invasion assay, 3 · 105 cells per millilitre were trans-
fected per well of a 24-well plate. For proliferation, 3 · 104
cells were seeded per well of a 96-w plate. Transfection com-
plexes were prepared in OptiMEM (Invitrogen) with 0.15 ll/96-
well or 2 ll/24-well of siPORT NeoFx transfection agent (Ambi-
on). Seventy-two hours post-transfection, the cells were lysed
for qRT-PCR analysis or Western blot, and assayed for prolifer-
ation or used to seed an in vitro invasion assay. For stable plas-
mid transfections 2 lg DNAs were used to transfect 3 · 105
cells in 2 ml in a 6-well plate. Forty-eight hours post-transfec-
tion the medium was supplemented with 800 lg/ml G418 and
selection was continued until themock-transfected cells were
killed. Surviving cells were expanded and single-cell cloned
by the limiting dilution method.
2.3. Detection of mature miR-29a by qRT-PCR
MiR-29a quantification was performed according to the pri-
mer/probe assay protocol provided by the manufacturer (Ap-plied Biosystems). For the RT step, 25 ng RNA was used to
generate cDNA. Quantitative PCR was performed by the addi-
tion of 2· Taqman Universal Mastermix containing the appro-
priate probe/primer mix. RNU6B expression was used for
internal normalisation. All reactions were performed on an
AB7500 instrument and relative expression was calculated
using the 2–DDCt method in SDS 1.3 software.
2.4. In vitro proliferation and invasion assay
The cell numbers were assessed 72 h post-transfection using
the acid phosphatase method.10 Invasion assays were per-
formed using MatrigelTM invasion assays (BD Bioscience). After
rehydration of the matrix, the medium underneath the insert
was replaced with ATCC media containing 5% (v/v) FCS. Sev-
enty-two hours after miRNA/siRNA transfections, the cells
were trypsinised, counted and resuspended inmedia contain-
ing 5% (v/v) FCS at a density of 1 · 106 cells/ml. Hundred
microlitres of cell suspension was added to each insert. The
cells were incubated at 37 C for 24–48 h, after which the in-
serts were stained, washed and the number of invasive cells
were determined by counting 10 random fields at 20·
magnification.
2.5. Detection of mRNA levels of siRNA knockdown gene
targets
RNAwas isolated from post-siRNA-transfected cells using the
RNeasy Mini Prep Kit (Qiagen) and quantified using a Nano-
dropTM spectrophotometer. For each reaction 500 ng RNA was
used to generate cDNA using a high-capacity cDNA reverse
transcription kit (Applied Biosystems). SybrGreenTM-based
qRT-PCR analysis was performed with specific primers
designed for each target. Primers used were (a) RAN (sense
5 0-GTTGGTGATGGTGGTACTGGAA-3 0, antisense 5 0-TCCTCT-
GTTGGTGTGGAACACT-3 0) and (b) B-actin (sense50-AGCAG-
GAGTATGACGAGTCCG-3 0, antisense 5 0-TCCCAGGGAGAC-
CAAAAGC-3 0). Each PCR contained 400 nM of sense and
antisense primers and 50 ng of cDNA. There were technical
as well as biological triplicates of each sample. Target gene
expression levels were normalised using b-actin.
2.6. Plasmid constructs
ThemiR-29a expression vector was constructed by PCR ampli-
fication of 250 bp sequence from DLKP genomic DNA. This
contained the complete pre-miR-29a sequence and additional
sequence upstream and downstream. The primers used were
sense 5 0-AAACCGGATCCGAGCCCAATGTATGCTGGATTTAG-3 0
(BamHI site underlined) and antisense 5 0-CCCAACTCGAGT-
TAAGCTTTGTTTTCTTAGTTCTTGTCCATGG-30 (HindIII site
underlined). PCR amplification was performed with KOD-XL
High Fidelity PCR kit (Merck/Novagen), using 0.7 lg template
in a 50 ll reaction mixture, according to the manufacturers
protocol. Thermal cycler conditions were 95 C for 2 min, fol-
lowed by 30 cycles of 94 C for 30 s, 60 C for 5 s and 72 C for
30 s. The PCR product was digested with BamHI/HindIII and
ligated into pSilencerTM 4.1-CMV-Neo vector (Ambion).
The RAN 3 0 UTR sequence was amplified from DLKP-A-de-
rived total RNA using custom primers: sense 5 0-
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underlined) and antisense 5 0-CCCGGATCCCGGCTTGCG-
TATCAACT TCACA-3 0 (BamHI site underlined). The amplified
PCR product was digested with HindIII/BamHI and cloned
downstream of gfp in pEGFP-C1 vector (Clontech).Fig. 1 – Endogenous miR-29a expression levels in DLKP
compared to DLKP-A. The samples were normalised using
RNU6B expression (n = 3).3. 2D Difference gel electrophoresis (2D DIGE)
DLKP-A cells were transfected with pre-miR-29a, anti-miR-29a
or their negative controls for 72 h and harvested. Lysates were
minimally labelled with 200 pmol/50 lg of protein with either
Cy3 (control) or Cy5 (test) for comparison on the same gel
(dyes from GE Healthcare). A pool containing equal amounts
of all samples was also prepared and labelled with Cy2 to be
used as an internal standard on all gels to aid image matching
and cross-gel statistical analysis. Three biological repeats of
each transfected sample were preformed. Twelve gels were
generated in total, with two gels per comparison.
Immobilised 24 cm linear pH gradient (IPG) strips (GE
Healthcare), pH 3–11, were rehydrated in rehydration buffer
(7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG Buffer, 50 mM
DTT) overnight. 2D DIGE was performed according to the
manufactures instructions and as previously described.11
The gels were scanned with a Typhoon variable mode imager
(GE Healthcare) and the subsequent gel images were imported
into the BVA module of DeCyder 6.5 software. Proteins were
defined as differentially regulated if the observed fold change
was ±1.2 (p < 0.05) in 1-WAY ANOVA between negative and
pre- or anti-miR-29a-treated samples.
3.1. Protein identification by mass spectrometry
Protein digestion and MALDI-TOF MS were performed as de-
scribed previously.11 For MALDI-TOF MS analysis, protein
identification was achieved using the PMF Profound database
search engine for peptide mass fingerprints. Low abundance
proteins were identified using LC–MS/MS with an Ettan MDLC
system (GE Healthcare) in high throughput configuration di-
rectly connected to a Finnegan LTQ (Thermo Electron). The
peptides were concentrated and desalted on RPC trap col-
umns (Zorbax 300SB C18, 0.3 mm · 5 mm, Agilent Technolo-
gies), and were separated on a nano-RPC column (Zorbax
300SB C18, 0.075 mm · 100 mm, Agilent Technologies) using
a linear acetonitrile gradient from 0% to 65% over 60 min.
All buffers used for nano LC separation contained 0.1% formic
acid (Fluka) as the ion-pairing reagent. Full scan mass spectra
were recorded in profile mode and tandem mass spectra in
centroid mode. The peptides were identified using the infor-
mation in the tandem mass spectra by searching against
the SWISS PROT database using SEQUEST.
3.2. Criteria for protein identification
For protein identification, artificial modifications of peptides
(carbamidomethylation of cysteines and partial oxidation of
methionines) were considered. Searches were also carried
out allowing for one missed cleavage. Protein identifications
were accepted if they could be established at greater than
99.8% probability and had at least two identified peptides.3.3. Western blotting
Western blotting was performed on protein cell lysates (7 M
urea, 2 M thiourea, 4% CHAPS, 30 mM Tris/HCl, pH 8.5) with
20 lg/lane of protein separated on a 12% NuPAGE Bis–Tris
gel (Invitrogen). After transfer to Hybond-ECL nitrocellulose
(GE Healthcare) the membranes were blocked and incubated
with rabbit anti-human RAN (Abcam) (1:500) with 5% (w/v)
fat-free milk powder in PBS containing 0.5% Tween-20, or
mouse anti-human GAPDH (1:3000) overnight at 4 C. Second-
ary antibodies were added after washing and bound antibody
was detected using enhanced chemiluminescence (ECL).
3.4. Flow cytometer analysis
Stable GFP overexpressing DLKP-A cells were trypsinised from
24-well plates and resuspended at <500 cells/ll. The benchtop
cytometer (Guava Technologies) was set up using GFP-nega-
tive DKLP-A cells to adjust the flow rate and gate the negative
population (green fluorescence <10 with PMT gain at 600 V).
GFP-transfected cells were then analysed and the intensity
of fluorescence was captured for 5000 cells per sample.
4. Results
4.1. MiR-29a is down-regulated in invasive cancer cells
An initial bioarray-based study in our laboratory comparing
microRNA expression in non- and highly invasive variants
of the lung cancer cell line DLKP identified several differen-
tially expressed miRNAs, one of which was miR-29a. Subse-
quent measurement by qRT-PCR confirmed that miR-29a
expression in the invasive variant was less than 45% of that
in the non-invasive cell line (Fig. 1).
4.2. MiR-29a decreases the invasive phenotype of cancer
cells in vitro
Though ectopic expression of miR-29a has previously been
shown to reduce the growth of lung cancer cells in vitro and
their tumourigenic potential in vivo,4 we were interested to
see if it would impact on the invasiveness of DLKP-A cells.
The cells were transfected with a short, artificial miR-29a mi-
mic (pre-miR) and seeded on ECM (MatrigelTM) 72 h later in a
Fig. 2 – Effect of miR-29a disregulation on invasion in DLKP-A cells. (A) Representative field of view of in vitro invasion inserts
at 20· magnification. (B) Quantification of relative numbers of invading cells representing average counts from 10 fields-of-
view per 2 inserts per sample ±SD, *p < 0.0005, **p < 10
–4. qRT-PCR to detect relative miR-29a levels in control (neg), anti- and
pre-miR-29a-transfected cells (C).
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transfected with a non-specific pre-miR control sequence,
we observed a 35–40% reduction in invading cells 24 h later
(Fig. 2a and b). The reciprocal experiment where endogenous
miR-29a activity was inhibited by transient transfection with a
complementary single-stranded RNA molecule (anti-mir) in-
creased the invasiveness of DLKP-A cells compared to the
control, though the effect was less pronounced possibly due
to the already highly invasive phenotype of these cells. To
confirm that the transfections resulted in the desired impact
on cellular levels of miR-29a, qRT-PCR was performed on ex-
tracted total RNA. Though the pre-miR treatment increased
the detected miR-29a by greater than 20-fold, we were unable
to detect any change in target levels subsequent to anti-miR
transfection (Fig. 2c). This is most likely due to the fact that
these molecules merely act as inhibitors by competitively
binding the target (mature miR-29a) but do not induce degra-
dation, as in the case of siRNA action.
The impact of exogenous upregulation ofmiR-29a in DLKP-
A cells led us to question whether the effect would prove to be
tissue-type specific or more general. The highly invasive hu-
man pancreatic carcinoma cell line, PANC-1, was transfected
with pre-miR and similarly displayed a 50% reduction in its
capacity to invade through the matrix (Fig. 3a and b). Quanti-
tative PCR suggested upregulation of miR-29a in these cells
compared to the negative control (Fig. 3c) though not to the
same extent achieved in the DLKP-A cell line.Fig. 3 – Effect of miR-29a upregulation on invasion in PANC-1 cel
under 20· magnification. (B) Quantification of relative numbers o
view in 2 Boyden chambers (error bar represents ±SE, p < 0.02). (C
miR-29a-transfected cells (n = 2, p = 0.13, error bars ± SE).Further confirmation of its impact on the invasiveness was
demonstrated in stable DLKP-A clones that constitutively
overexpressed miR-29a. These were generated by cloning a
250 bp genomic fragment from DLKP-derived DNA, that in-
cluded the full miR-29a sequence and flanking sequence, into
an expression vector. Stable clones were found to express ma-
ture miR-29a at varying levels (Fig. 4b). The invasiveness of a
sub set of these clones was measured and found to correlate
negatively with expression of miR-29a (Fig. 4a). It was also
found that the proliferation of these stable clones was re-
duced compared to control cells (Fig. 4c); this was not ob-
served in the transient transfections.
4.3. Proteomic profiling of cells overexpressing miR-29a
A small number of gene targets of miR-29a activity in vitro or
in vivo have been verified experimentally in several recent
publications. These include Tcl1,7 the DNA methyltransfer-
ase enzymes, DNMT3A and B,4 Mcl-1,3 ColA1,12 tristetrapro-
lin13 and CDC42.14 In addition, depending on which software
algorithm is employed, several hundred more downstream
targets can be in silico predicted. To gain a better understand-
ing of the range of proteins affected either directly or indi-
rectly by this miRNA in vitro, we applied 2D DIGE analysis
of lysates from DLKP-A cells transfected transiently with
exogenous pre- and anti-miR-29a compared to cells treated
with the appropriate non-specific, negative controls. Asls. (A) Representative field of view of in vitro invasion inserts
f invading cells representing average counts from 10 fields of
) qRT-PCR to detect relative miR-29a levels in control and pre-
Fig. 4 – Invasive phenotype of DLKP-A clones stably transfected with miR-29a or Neg-mir expression vector. (A) Relative
invasion of each of the clones compared to a negative-mir clone. Neg-Mir represents a clone derived from cells stably
transfected with the expression vector incorporating a non-specific sequence of similar length to the mir-29a insert (n = 3,
error bars ± SE). (B) Relative expression of miR-29a in stable clones (n = 3, error bars ± SE). (C) Cell proliferation of the 5 clones
relative to Neg Pre-mir, (p < 0.001 in all samples, error bars ± SE).
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ments that were both increased and decreased compared
to the control-transfected cells. To simplify the subsequent
analysis we focused on the proteins that were down-regu-
lated in response to pre-miR treatment and up-regulated in
anti-miR-treated cells. These comprised the primary list of
75 potentially ‘direct’ targets of miR-29a activity (Table 1).
The proteins with the opposite trend in expression, i.e. up-
regulated upon treatment with pre-miR-29a or down-regu-
lated upon treatment with anti-miR-29a, would be expectedto be indirect, downstream targets of miR-29a action. How-
ever, it is likely that some of the proteins on the primary list
could also be indirect targets whose expression is affected by
the action of a miR-29a target gene. In addition, several pro-
teins were identified at more than one spot location suggest-
ing the presence of post-translational modifications on these
molecules.
The range of differential expression of the identified pro-
teins was modest with the greatest change being 1.63-fold
down-regulation of macrophage migration inhibitory factor
Table 1 – Proteins differentially regulated after transient transfection of invasive DLKP-A lung cancer cells with Pre- or Anti-
miR-29a. The cell lysates were separated by 2D DIGE followed by identification of differential protein spots by either MALDI-
TOF or LC–MS. Identifications were only sought for proteins up-regulated in response to anti-miR-29a transfection (+’ve FC) or
down-regulated subsequent to pre-miR-29a transfection ()‘ve FC). A fold change cut-off of 1.2 was applied with a p-value <
0.05. Prediction of the presence of a miR-29a seed region in the 3 0 UTR of each gene was performed with RNA hybrid software.
Gene symbol Gene name Protein ID GenBank
ID
Mass
(Da)
Fold
change
ANOVA Predicted
target of
miR-29a
Biological
process
HIST4H4* Histone H4 gi|75061938| NM_175054 11,360 –1.64 0.034 Chromatin
packaging and
remodelling
MIF Macrophage migration
inhibitory factor
gi|1170955| NM_002415 12,468 –1.63 0.035 Macrophage-
mediated
immunity
ISG15 ISG15 ubiquitin-like
modifier
gi|386837| NM_005101 17,910 –1.63 0.0026 Proteolysis
PRDX1* Peroxiredoxin 1 gi|548453| NM_002574 22,096 –1.53 0.035 Antioxidation
and free radical
removal
CFL1 Cofilin-1 gi|116848| NM_005507 18,491 –1.53 0.0019 Apoptosis
PEBP1 Phosphatidylethanolamine-
binding protein 1
gi|1352726| NM_002567 21,044 –1.53 0.0004 x Other signal
transduction
HIST4H4* Histone H4 gi|75061938| NM_175054 11,360 –1.46 0.0011 Chromatin
packaging and
remodelling
LGALS1 Histidine triad nucleotide-
binding protein 1
gi|42542978| NM_002305 14,910 –1.45 0.0005 Cell adhesion;
other immune
and defence;
induction of
apoptosis
RPL11 60S ribosomal protein L11 gi|51701767| NM_000975 20,240 –1.45 0.0005 Protein
biosynthesis
RPS12 40S ribosomal protein S12 gi|133742| NM_001016 14,517 –1.43 0.012 Protein
biosynthesis
GMFB Glia maturation
factor beta
gi|46577593| NM_004124 16,703 –1.43 0.0021 x Neurogenesis
BTF3L4 Transcription factor BTF3
homologue 4
gi|75042131| NM_152265 17,260 –1.43 0.0019 Unclassified
CLPP ATP-dependent Clp protease
proteolytic subunit
gi|3023512| NM_006012 30,161 –1.42 0.03 Proteolysis
FABP5 Fatty acid-binding protein,
epidermal
gi|232081| NM_001444 15,155 –1.42 0.005 Lipid and fatty
acid transport
HIBCH 3-Hydroxyisobutyryl-CoA
hydrolase
gi|146324905| NM_014362 43,454 –1.42 0.005 Carbohydrate
metabolism
and fatty acid
beta-oxidation
PPIB Cyclosporin gi|1310882| NM_000942 19,700 –1.41 0.027 x Protein folding;
nuclear
transport;
immunity and
defence
PSMB4 Proteasome subunit beta
type-4 precursor
gi|116242733| NM_002796 29,186 –1.41 0.0024 Proteolysis
PPIA* Peptidylprolyl isomerase A
(cyclophilin A)
gi|75766275| NM_021130 18,030 –1.4 0.0045 x Protein folding;
nuclear
transport;
immunity and
defence
SOD1 Superoxide dismutase gi|134611| NM_000454 15,926 –1.39 0.043 Immunity and
defence
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Table 1 – (continued)
Gene symbol Gene name Protein ID GenBank
ID
Mass
(Da)
Fold
change
ANOVA Predicted
target of
miR-29a
Biological
process
GSTK1 Glutathione S-transferase
kappa 1
gi|12643338| NM_015917 25,480 –1.39 0.0015 Translational
regulation
PPIA* Peptidylprolyl isomerase A
(cyclophilin A)
gi|3659980| NM_021130 18,090 –1.36 0.02 x Protein folding;
nuclear transport;
immunity and
defence
TPx-B Thioredoxin Peroxidase B gi|9955016| NM_005809 21,680 –1.36 0.0011 Unknown
APRT Adenine
phosphoribosyltransferase
gi|114074| NM_000485 19,595 –1.35 0.015 Unclassified
PPIA* Peptidylprolyl isomerase A
(cyclophilin A)
gi|75766275| NM_021130 18,030 –1.35 0.0091 x Unknown
IGH2bM35a Immunoglobulin heavy
chain
gi|7161037| AJ253041 10,600 –1.35 0.004 Unknown
RAN RAS-related nuclear protein gi|5107684| NM_006325 23,300 –1.35 0.00024 RNA localisation;
intracellular
signalling
cascade; nuclear
transport and cell
cycle
ATP6V1E1 Vacuolar ATP synthase
subunit E 1
gi|549207| NM_001696 26,129 –1.34 0.013 Nucleoside,
nucleotide and
nucleic acid
metabolism
PRDX1* Peroxiredoxin 1 gi|548453| NM_002574 22,096 –1.34 0.0035 Antioxidation and
free radical
removal
HINT1 Histidine triad nucleotide-
binding protein 1
gi|1708543| NM_005340 13,793 –1.33 0.0048 Unclassified
GNB2L1 Guanine nucleotide-binding
protein subunit beta-2-like 1
gi|54037164| NM_006098 35,055 –1.32 0.048 Signal
transduction;
protein targeting
PRDX3 Peroxiredoxin 3 isoform b gi|32483377| NM_006793 26,110 –1.32 0.0031 Antioxidation and
free radical
removal
ARL3* ADP-ribosylation factor-like
protein 3
gi|543851 NM_004311 20,443 –1.31 0.046 x General vesicle
transport
PRDX1* Peroxiredoxin 1 gi|55959887| NM_002574 19,130 –1.31 0.019 Antioxidation and
free radical
removal
PPIA* Peptidylprolyl isomerase A
(cyclophilin A)
gi|2981764| NM_021130 18,090 –1.31 0.0069 x Unknown
SFRS1 Splicing factor, arginine/
serine-rich 1
gi|45708738| NM_006924 22,560 –1.29 0.042 mRNA splicing
ERP29 Endoplasmic reticulum
protein ERp29 precursor
gi|6015110| NM_006817 28,975 –1.29 0.0027 Constitutive
exocytosis
CMPK1 Cytidine monophosphate
kinase
gi|12644008| NM_016308 22,208 –1.29 0.00039 x Pyrimidine
metabolism
C20orf45 Chromosome 20 open
reading frame 45
gi|26392626| NM_016045 21,481 –1.28 0.019 Unclassified
PSMA2* Proteasome subunit alpha
type-6
gi|46397655| NM_002791 27,382 –1.28 0.017 Proteolysis
NDKA Nucleoside diphosphate
kinase A
gi|127981| NM_198175 17,138 –1.28 8.40E–05 Pyrimidine
metabolism
VBP1 VHL-binding protein-1 gi|1465751| NM_003372 19,520 –1.27 0.015 Protein folding
and protein
complex
assembly
HPRT Hypoxanthine
phosphoribosyltransferase
gi|459815| NM_000194 24,730 –1.27 0.0046 Purine
metabolism
THOC6 THO complex subunit 6
homologue
gi|74759455| NM_024339 37,511 –1.26 0.023 Unclassified
(continued on next page)
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Table 1 – (continued)
Gene symbol Gene name Protein ID GenBank
ID
Mass
(Da)
Fold
change
ANOVA Predicted
target of
miR-29a
Biological
process
PRDX1* Peroxiredoxin 1 gi|55959887| NM_002574 19,130 –1.26 0.015 Antioxidation and
free radical
removal
Sfrs3 Splicing factor,
arginine/serine-rich 3
gi|51338673| NM_003017 19,318 –1.26 0.011 mRNA splicing
CFL1 Cofilin-1 gi|116848| NM_005507 18,491 –1.26 0.0024 Cell structure
PARK7 Parkinson disease
(autosomal recessive,
early onset) 7
gi|42543006| NM_007262 20,060 –1.26 0.00072 Cell proliferation
and differentiation
GNB3 Guanine nucleotide-
binding protein
subunit beta-3
gi|121011| NM_002075 37,197 –1.25 0.048 G-protein mediated
signalling
GRB2 Growth factor
receptor-bound
protein 2
gi|28876| NM_002086 18,620 –1.25 0.0059 Receptor protein
tyrosine kinase
signalling pathway
ESD Esterase D/
formylglutathione
hydrolase
gi|12654663| NM_001984 32,020 –1.25 0.0013 Unclassified
NDUFA10 NADH
dehydrogenase
(ubiquinone) 1 alpha
subcomplex
gi|13097333| NM_004544 41,070 –1.25 0.0013 Oxidative
phosphorylation
LYPLA2 Lysophospholipase II gi|41017276| NM_007260 24,721 –1.25 0.0003 Lipid metabolism;
cell proliferation
and differentiation
PRDX1* Peroxiredoxin 1 gi|55959887| NM_002574 19,130 –1.24 0.037 Antioxidation and
free radical
removal
FKBP3 FK506-binding
protein 3
gi|232096| NM_002013 25,161 –1.24 0.03 Protein folding and
cell cycle control
HSPB1 Heat shock protein
beta-1
gi|19855073| NM_001540 22,769 –1.24 0.03 Protein folding and
stress response
CYC Cytochrome c gi|42560195| NM_018947 11,741 –1.24 0.018 x Oxidative
phosphorylation;
apoptotic processes
ANXA1 Annexin A1 gi|113944| NM_000700 38,690 –1.24 0.006 Fatty acid
metabolism;
receptor-mediated
signal transduction
and cell motility
PSMA2* Proteasome subunit
alpha type-2
gi|39644890| NM_002787 24,970 –1.23 0.0096 Proteolysis
PRDX6 Peroxiredoxin-6 gi|1718024| NM_004905 25,019 –1.22 0.041 x Antioxidation and
free radical
removal
PGAM1 Phosphoglycerate
Mutase
gi|67464305| NM_002629 29,970 –1.22 0.0021 Glycolysis
GALE UDP-galactose-4-
epimerase
gi|68056598| NM_001008216 38,257 –1.21 0.037 Carbohydrate
metabolism
PSMB2 Proteasome subunit
beta type-2
gi|1709762| NM_002794 22,822 –1.21 0.029 x Proteolysis
ANXA2 Annexin A2 gi|56967119| NM_001002858 36,640 –1.21 0.0059 x Intracellular
protein traffic;
Mesoderm
development; Cell
structure and
motility
PAFAH1B2 Platelet-activating
factor
acetylhydrolase IB
subunit beta
gi|55977293| NM_002572 25,553 –1.21 0.0043 Unclassified
3112 E U R O P E A N J O U R N A L O F C A N C E R 4 5 ( 2 0 0 9 ) 3 1 0 4 –3 1 1 8
Table 1 – (continued)
Gene symbol Gene name Protein ID GenBank
ID
Mass
(Da)
Fold
change
ANOVA Predicted
target of
miR-29a
Biological
process
CACYBP Calcyclin-binding
protein
gi|46576651| NM_014412 26,194 –1.2 0.036 Proteolysis
HIBADH 3-Hydroxyisobutyrate
dehydrogenase
gi|12643395| NM_152740 35,306 –1.2 0.0074 Amino acid
biosynthesis and
amino acid
catabolism
IGv Immunoglobulin
heavy chain subgroup
VIII V-D-J region
gi|348186| 13,830 –1.2 0.0036 Unclassified
KIAA1598 Formin-like
(pthr23213:sf23)
gi|156637366| NM_018330 71596 1.21 0.034 Cell motility
RuvB-like 2 48 kDa TATA box-
binding protein-
interacting
protein
gi|28201890| NM_006666 51125 1.22 0.049 mRNA
transcription
regulation;
Embryogenesis;
Mesoderm
development
ACTC1 Alpha-actin-1 gi|55976646| NM_005159 42024 1.22 0.036 X Exocytosis;
Endocytosis;
Transport;
Cytokinesis;
Cell structure
ATP5A1 ATP synthase subunit
alpha, mitochondrial
precursor
gi|158514235| NM_001001937 59714 1.22 0.013 UnClassified
EEF1A1 Eukaryotic
translation
elongation factor 1
alpha 1
gi|31092| NM_001402 50450 1.23 0.022 Translational
regulation
ENO1 Enolase-alpha gi|31873302| NM_001428 47420 1.24 0.055 Glycolysis
PGK1 Phosphoglycerate
kinase 1
gi|48145549| NM_000291 44980 1.24 0.036 Glycolysis
CCT3 T-complex protein 1
subunit gamma
gi|66774185| NM_005998 60495 1.24 0.024 Protein
folding;Protein
complex assembly
SERBP1 Plasminogen
activator inhibitor 1
RNA-binding protein
gi|52783206| NM_001018067 44939 1.24 0.0036 UnClassified
EF2 Elongation factor 2 gi|119172| NM_001961 95277 1.25 0.051 Protein
biosynthesis
TRXR1 Thioredoxin
reductase 1
gi|50403780| NM_003330 55490 1.25 0.02 Electron
transport;Other
metabolism
LOC652797 Pyruvate kinase
isozymes M1/M2
gi|20178296| XM_001719890 57900 1.27 0.024 Unknown
GRP94 Heat shock protein
gp96 precursor
gi|15010550| NM_003299 90350 1.28 0.055 Protein
folding;Stress
response
ALDH1A1 Aldehyde
dehydrogenase 1
gi|2183299| NM_000689 55440 1.28 0.047 Other carbon
metabolism
PTBP1 Polypyrimidine tract-
binding protein 1
gi|131528| NM_002819 57186 1.29 0.0074 mRNA splicing
DDT D-dopachrome
decarboxylase
gi|2828192| NM_001355 12704 1.35 0.039 Macrophage-
mediated
immunity
* Indicates proteins that were identified at more than one spot location suggesting isoforms with post-translational modifications
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range 1.2–1.4-fold. In silico analysis of the 3 0 UTRs of these
genes predicted that only 14 contained potential ‘seed’ se-
quences, i.e. at least 6 matches between nt2–8 at the 5 0 endof miR-29a. Analysis of the proteins on the primary list to
investigate the cellular functions that they have been previ-
ously associated with revealed a bias towards proliferation,
apoptosis, secretion and motility (Table 1).
Fig. 5 – Impact of RAN-specific knockdown on DLKP-A cells using 2 independent siRNA sequences. (A) Specific knockdown of
RAN by transient transfection of siRNA in DLKP-A reduces in vitro invasion (±SD, p < 10–6). (B) proliferation, (±SD, *p < 0.02,
**p < 0.0001), Kif11 denotes kinesin positive control. Ntmt = no treatment, Scrm = scrambled control siRNA. (C) Confirmation of
siRNA-induced knockdown of RAN mRNA by qPCR (±SE, n = 2). (D) protein by Western blot. (E) RNA hybrid software-predicted
interaction between miR-29a and the RAN 3 0 UTR.
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A small panel of the identified proteins was chosen to inves-
tigate the impact of knocking down their expression individ-
ually in vitro. These targets included Annexin A2 (ANXA2),
growth factor receptor-bound 2 (GRB2), macrophage migra-
tory inhibitory factor (MIF) – which had the highest foldchange after pre-miR-29a treatment – and Ras-related nuclear
protein (RAN). The latter three were chosen based on previous
associations with an invasive phenotype or metastatic dis-
ease, whereas ANXA2 was picked based on in silico predictions
of a miR-29a binding site. Though siRNA-mediated knock-
down was verified in all cases by qRT-PCR (data not shown),
only RAN depletion impacted on the invasiveness of DLKP-A
Fig. 6 – (A) Transient transfection of DLKP-A cells with pre-miR-29a has no impact on cellular levels of RAN mRNA compared to
negative pre-mir control treatment (±SE, n = 3). (B) 3-D spot image of same samples analysed by 2D DIGE, the quantity of RAN
protein is reduced by >30% (p < 0.05). (C) Flow cytometric analysis of GFP fluorescence in mixed, stable, GFP-30 UTRRAN
expressing DLKP cells. Each ‘bin’ represents the cells with similar fluorescent intensities from low to high.1–6
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duced by 40-80% compared to the invasiveness of the control-
transfected cells (Fig. 5a). In addition, cell proliferation was
reduced by 30–40% over a 72-h period (Fig. 5b). Knockdown
was confirmed at both mRNA and protein levels (Fig. 5c and
d). Of the four proteins targeted, only ANXA2 contained a pre-
dicted seed region though the RNA hybrid software (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/) did reveal a
weak target site for miR-29a in the RAN 3 0 UTR (Fig. 5e).
4.5. Is RAN a direct target of MiR-29a?
The classical mode of miRNA action typically inhibits target
protein translation without concurrent reduction in mRNAabundance. In DLKP-A cells transfected with miR-29a, no sig-
nificant change in RAN transcript levels was detected by qPCR
(Fig. 6a) despite a 35% reduction in RAN protein when ana-
lysed by 2D DIGE (Fig. 6b). Western blots on the same samples
could not reproducibly demonstrate this change in RAN
expression (data not shown) as this method lacks the sensi-
tivity of the 2D DIGE approach. Having made the connection
between miR-29a expression levels, RAN expression and the
invasive phenotype, we wished to establish whether miR-29a
impacted on RAN expression by direct interaction with the
mRNA transcript. The RAN 3 0 UTR sequence was cloned by
PCR from DLKP genomic DNA and placed downstream of a
GFP reporter gene. DLKP-A cells, stably expressing this GFP-
3 0 UTRRAN reporter fusion, were generated and transiently
Table 2 – Panther classification, according to molecular function, of differentially expressed proteins in cells treated with
either Pre- or Anti-miR-29a. A total of 50 proteins were classified using the DAVID bioinformatics resource (http://
david.abcc.ncifcrf.gov/). Count represents number of proteins in each classification group and % represents the percentage of
the list of 50 proteins in each group.
Molecular function Count % p-Value GeneBank accession no.
Peroxidase 4 7.27 7.18E–04 NM_006793, NM_005809, NM_002574, NM_004905
Oxidoreductase 7 12.73 0.003381 NM_152740, NM_000454, NM_006793, NM_005809,
NM_004544, NM_002574, NM_004905
Transfer/carrier
protein
6 10.91 0.00479 NM_015917, NM_001444, NM_018947, NM_002567,
NM_001002858, NM_000700
Serine protease
inhibitor
11 20.00 0.005989 NM_015917, NM_016045, NM_021130, NM_002305,
NM_002796, NM_001008216, NM_024339, NM_002791,
NM_002086, NM_002794, NM_002787
Non-receptor serine/
threonine protein
kinase
15 27.27 0.033791 NM_000485, NM_006817, NM_002796, NM_152265,
NM_002075, NM_000975, NM_014362, NM_014412,
NM_015917, NM_001540, NM_002415, NM_005809,
NM_002629, NM_175054, NM_002794
Other transferase 4 7.27 0.035344 NM_015917, NM_016045, NM_001696, NM_014362,
Annexin 4 7.27 0.039542 NM_198175, NM_001002858, NM_005101, NM_000700
Non-motor actin-
binding protein
13 23.64 0.042818 NM_006817, NM_001008216, NM_000975, NM_014362,
NM_002791, NM_002086, NM_005507, NM_001444,
NM_002305, NM_001540, NM_006012, NM_002629,
NM_002787
Protease 5 9.09 0.052485 NM_002796, NM_006012, NM_002791, NM_002794,
NM_002787
Chaperone 3 5.45 0.058427 NM_001540, NM_002013, NM_003372
Other isomerase 4 7.27 0.078832 NM_021130, NM_000194, NM_002572, NM_002013
Neuropeptide 4 7.27 0.091305 NM_015917, NM_002567, NM_002075, NM_014362
Other proteases 4 7.27 0.096733 NM_002796, NM_002791, NM_002794, NM_002787
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Flow cytometry analysis revealed that the mean cell fluores-
cence was not significantly impacted across this mixed popu-
lation of stable cells in response to pre-miR-29a transfection
(Fig. 6c).
5. Discussion
Several recent publications have established miR-29 family
members as important molecules in suppressing tumouri-
genic phenotypes in cell line models. In vivo, their expression
levels have been shown to positively correlate with favourable
outcome in AML patients.6 Though several important target
genes have been identified, typically by homology-based
analysis of 3’UTR regions, it is expected that most miRNAs
have the potential to influence the expression of many, if
not hundreds of target proteins. The list of potential targets
identified in this study provides some interesting clues to
the different pathways and functions that miR-29a might im-
pact on in its role as an ‘anti-oncomir’.
Having established that miR-29a was down-regulated in
invasive lung and pancreatic cell lines, we observed a signifi-
cant reduction in this phenotype upon re-introduction of
exogenousmiR-29a. Though upregulation ofmiR-29a has been
shown to decrease the tumourigenic potential of A549 cells4
this is the first demonstration of a role in modulating the
in vitro invasive ability of cancer cells. In addition the effect
is not cell- or organ-type specific having demonstrated func-
tional impact in both lung and pancreatic cancer cell lines.
Mott and colleagues described a functional role for miR-29b
in chologiocarcinomas where its enforced expression reducedthe cellular levels of Mcl-1 and sensitised cells to TRAIL-med-
iated cytotoxicity.3 Furthermore, Pekarsky and colleagues pro-
vide evidence that miR-29b is involved in suppressing
expression of the Tcl1 oncogene which is a causal agent in
CLL.7
We have shown that invasive DLKP-A cells that stably
overexpressed miR-29a were also found to have reduced pro-
liferation compared to their control-transfected counterparts
and this might be, in part, explained by the ability of miR-29
family members to down regulate Mcl-1 activity.
The 2D DIGE analysis demonstrated that modifying the
cellular concentration of miR-29a impacted on the levels of a
large number of proteins, with diverse cellular functions.
Two lists of differentially expressed proteins were generated
using this approach. In an attempt to focus on direct targets
of miR-29a we limited our analysis to the proteins up-regu-
lated after anti-mir treatment and down-regulated after pre-
mir transfection – referred to as the primary list. The assump-
tion here was that the reciprocally effected proteins must be
secondary downstream targets of action. Of course further
proof would be required to demonstrate that the transcripts
coding for the proteins on the primary list are actually directly
bound by miR-29a.
Using the ‘RNA hybrid’ software programme to analyse the
genes on our primary list, 14 were predicted to contain a
‘seed’ binding site in their 3 0 UTR (at least 6nt match between
nt2–8 at 5 0 end of the miR-29a). This represents less than 20%
of the proteins on the list suggesting that either (a) most of
the identified proteins are secondary targets ofmiR-29a action
or (b) a canonical seed region is not imperative for miRNA-
UTR interaction.
E U R O P E A N J O U R N A L O F C A N C E R 4 5 ( 2 0 0 9 ) 3 1 0 4 –3 1 1 8 3117Ontological analysis of the differentially expressed
proteins revealed a bias towards 4–5 main biological functions
including proliferation, apoptosis, motility, differentiation
and mutagenesis (Table 1). Likewise, analysis of the
main groupings according to molecular function demon-
strated an enrichment of peroxidase and oxidoreductase
activities (Table 2), again in keeping with previous reports of
association of these types of proteins with metastatic tumour
formation.15,16 The predominance of these groupings is in
keeping with a role for miR-29a in modulating the aggressive-
ness/invasive potential of cancer cell lines and possibly tu-
mours in vivo. Several of the genes identified have well-
documented roles in stimulating cellular invasion, such as
MIF (macrophage migratory inhibitory factor) which has been
implicated in prostate, colon and other cancer types.17,18
GRB2 (growth factor receptor-bound protein 2) is a crucial
adaptor protein that mediates cell signalling from the surface
membrane receptors to their downstream targets and indeed
is a current target for the development of anticancer thera-
peutics.19,20 It was interesting to observe that, despite being
identified in the proteomic analysis, subsequent qPCR analy-
ses of both miR-29a-transfected and untransfected cells indi-
cated extremely low levels of GRB2 transcript (data not
shown).
Several peroxiredoxin family members were identified as
being down-regulated in response to miR-29a transfection
supporting several reports correlating their expression with
cancer development and recurrence.21,22 As antioxidants
these proteins might be expected to play a protective role
against elimination of cancerous cells in vivo.
Enolase (ENO1) is another protein with a recognised role in
cellular invasion as a plasminogen-binding receptor.23
Intriguingly, an alternative splice-variant of this gene, c-
myc-promoter binding protein, acts as a transcriptional
repressor of c-myc which in turn has been shown recently
to repress expression of miR-29a.8 More recently, ENO1 has
also been shown to suppress the Notch1 receptor/YY1-depen-
dent activation of c-myc.24 These observations suggest the
possibility of a feedback loop where increased c-myc expres-
sion reduces miR-29a levels hence releasing a translational
block on ENO1 which in turn antagonises the activation of
c-myc, thereby releasing miR-29a expression and so on.
SFRS1 (splicing factor, arginine/serine-rich 1) was found
to be decreased in Herceptin-treated ErbB2-overexpressing
cell lines and was also shown to affect cellular motility.25,26
Our analysis also reveals a predicted miR-29a binding site
in the 3 0 UTR of SFRS1. Galectin-1 (LGALS1) has an estab-
lished role in the invasive and metastatic potentials of
cells in vitro and in vivo.27,28 Interestingly there were also
examples of genes identified here that have previously
been associated with reduction of this phenotype or nega-
tively correlating with poor outcome in clinical studies.
Both annexins A1 and A2 are identified as miR-29a-regu-
lated genes in this study and both have previously been
shown to reduce cell migration in vitro and to be lost in
some nodal metastases.29,30 Indeed ANXA2 has a predicted
6nt seed match in its 3 0 UTR. The same is true of RKIP
(Raf-1 kinase inhibitory protein) which is typically reported
to have a metastasis-suppressor role in tumours.31 How-
ever, most of the proteins that have already been linkedto cancer or invasion would be expected to be up-regulated
based on the reports in the literature in this phenotype –
supporting the theory of an anti-invasive role for miR-29a
in cells.
Rather than focusing solely on the genes that contained
predicted miR-29a target sites in their 3 0 UTRs we chose a
small group of targets representing proteins with established
roles in the phenotype of interest. Knockdown of the expres-
sion levels of these targets individually with siRNA resulted
in a phenotypic impact only in the case of RAN (Ran-
GTPase). Indeed the degree to which invasion and prolifera-
tion were inhibited in the DLKP-A cells was similar to that
observed in the miR-29a stably transfected cells. RAN is a
small 25 kDa protein that acts as a mediator of nucleocyto-
plasmic transport. In the nucleus it is loaded with GTP by
the chromatin-associated RCC1 complex allowing it to inter-
act with certain transport partners to shuttle proteins and
small RNAs (including miRNAs) out of the nucleus.32 It is
intriguing to consider the possibility of miR-29a self-regulat-
ing its cytoplasmic concentration by directly modulating
RAN translation. RAN is also involved in nuclear segmenta-
tion during mitosis where it directs the assembly of the mi-
totic spindle. Kurisetty and colleagues have recently
demonstrated that RAN overexpression in a non-invasive
rat mammary epithelial cell line results in increased anchor-
age-independent growth, cell attachment, invasion through
MatrigelTM in vitro and metastasis in rats.33 Also, Xia and
colleagues found that acute silencing of RAN in various
tumour cell types causes aberrant mitotic spindle formation,
mitochondrial dysfunction and apoptosis.34 This dependency
was not reflected in other normal cell types.
Having established that miR-29a influences the cellular
concentration of a critical protein that can impact on both
invasion and proliferation we wanted to establish whether
the RAN transcript was a direct target of miR-29a action.
The observation that the average fluorescence signal in cells
stably expressing a GFP reporter gene fused to the Ran 3 0
UTR was not significantly reduced suggests that the impact
on endogenous Ran protein expression (35% down-regulated
in proteomics analysis) might be secondary to the effect of
miR-29a.
Irrespective of whether RAN is a direct or indirect target of
miR-29a activity we provide evidence suggesting that it is via
this mechanism, in part at least, that miR-29a influences the
invasive and proliferative capacity of cancer cells. Indeed,
the RAN-dependent status of many tumours34 raises the pos-
sibility of augmenting miR-29a expression as a potential ther-
apeutic intervention.Conflict of interest statement
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